HEALTHSTAT NEWS
STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
Enliven Therapeutics' leukemia drug, ELVN-001, achieved a 48% major molecular response rate in patients with chronic myeloid leukemia (CML) at 24 weeks. The drug showed higher efficacy in earlier-stage CML patients and outperformed existing treatments from Novartis and Merck in early-stage study results.
Mentioned
Related Signal
Adjacent reporting
- GSK reports promising early results in ovarian and womb cancer drug trial
- Pancreatic cancer breakthrough as scientists develop new drug that 'doubles survival rate' of silent killer
- STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
- After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
- WATCH: How a new drug could lengthen lives of pancreatic cancer patients
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug